• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    11/22/23 8:06:47 AM ET
    $AFIB
    $APLM
    $ATHE
    $CRIS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AFIB alert in real time by email

    Gainers

    • Heart Test Laboratories (NASDAQ:HSCS) stock rose 23.9% to $0.24 during Wednesday's pre-market session. The company's market cap stands at $5.3 million.
    • PaxMedica (NASDAQ:PXMD) shares moved upwards by 23.24% to $0.99. The market value of their outstanding shares is at $1.0 million.
    • NeuroOne Medical Tech (NASDAQ:NMTC) stock moved upwards by 14.68% to $1.46. The market value of their outstanding shares is at $34.8 million.
    • Apollomics (NASDAQ:APLM) shares increased by 14.18% to $0.92. The company's market cap stands at $81.9 million.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) shares rose 13.99% to $0.57. The market value of their outstanding shares is at $5.3 million.
    • Curis (NASDAQ:CRIS) stock increased by 12.32% to $9.57. The market value of their outstanding shares is at $56.3 million.

    Losers

    • UpHealth (NYSE:UPH) stock declined by 20.2% to $0.63 during Wednesday's pre-market session. The company's market cap stands at $10.8 million.
    • Alterity Therapeutics (NASDAQ:ATHE) shares fell 15.97% to $2.0. The market value of their outstanding shares is at $8.1 million.
    • Nexalin Technology (NASDAQ:NXL) stock decreased by 15.52% to $0.31. The market value of their outstanding shares is at $2.2 million.
    • SILO Pharma (NASDAQ:SILO) stock fell 11.96% to $1.62. The company's market cap stands at $5.0 million.
    • Acutus Medical (NASDAQ:AFIB) stock declined by 10.44% to $0.25. The market value of their outstanding shares is at $7.2 million.
    • TRACON Pharma (NASDAQ:TCON) stock declined by 10.05% to $0.2. The market value of their outstanding shares is at $6.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AFIB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AFIB
    $APLM
    $ATHE
    $CRIS

    CompanyDatePrice TargetRatingAnalyst
    Curis Inc.
    $CRIS
    5/19/2025$17.00Buy
    H.C. Wainwright
    NeuroOne Medical Technologies Corporation
    $NMTC
    5/5/2025$1.45Buy
    Ladenburg Thalmann
    Alterity Therapeutics Limited
    $ATHE
    2/3/2025Speculative Buy → Hold
    The Benchmark Company
    Alterity Therapeutics Limited
    $ATHE
    12/12/2024$8.00Buy
    Maxim Group
    Curis Inc.
    $CRIS
    11/17/2023$26.00Buy
    Truist
    Curis Inc.
    $CRIS
    4/4/2022Outperform → Mkt Perform
    Raymond James
    UpHealth Inc.
    $UPH
    3/31/2022$6.00 → $1.00Buy → Hold
    Lake Street
    NeuroOne Medical Technologies Corporation
    $NMTC
    3/29/2022$6.00 → $2.00Buy → Hold
    Craig Hallum
    More analyst ratings

    $AFIB
    $APLM
    $ATHE
    $CRIS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Business Officer Wambeke David J. bought $670,400 worth of shares (1,000,000 units at $0.67) (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    3/3/26 8:49:19 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Weisblum Eric bought $2,075 worth of shares (5,000 units at $0.41), increasing direct ownership by 2% to 216,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    12/16/25 6:34:59 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Chief Executive Officer Weisblum Eric bought $735 worth of shares (2,000 units at $0.37), increasing direct ownership by 0.95% to 211,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    11/21/25 6:35:50 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    $AFIB
    $APLM
    $ATHE
    $CRIS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit

    MELBOURNE, Australia and SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced  that David Stamler, M.D., Chief Executive Officer of Alterity, will participate in the Bell Potter Healthcare Horizons Summit taking place 12-13 March 2026 in Sorrento, Australia. At the conference, Dr. Stamler will participate in a fireside chat entitled, "Optimising Late-stage Clinical Trials to Increase the Odds," and will also host 1-on-1 investor meetings. About Alterity Therapeutics Limited  Alterity Therap

    3/9/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Next-Generation Platforms Scale Across Energy, Wellness, and Smokeless Consumer Segments

    Issued on behalf of Doseology Sciences Inc.Equity-Insider.com VANCOUVER, BC, March 5, 2026 /CNW/ -- Consumers are voting with their wallets, and zero-sugar is winning. Zero-sugar beverages are driving 6x more dollar growth than regular varieties as buyers actively choose clean-label products with natural sweeteners and functional ingredients[1]. The global market is forecast to expand from $350 billion in 2024 toward $500 billion by 2029, fueled by health-conscious consumers who want naturally functional products without heavy processing[1]. This structural shift is creating validated demand for precision-dosed, portable formats across energy and wellness categories, positioning Doseology Sc

    3/5/26 9:00:00 AM ET
    $HLF
    $NHTC
    $NMTC
    Other Pharmaceuticals
    Health Care
    Consumer Specialties
    Consumer Discretionary

    Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor

    MELBOURNE, Australia and SAN FRANCISCO, March 04, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that Daniel O. Claassen, M.D., M.S., was appointed Chief Medical Advisor and will begin his role in March 2026. As a tenured professor, Dr. Claassen will also retain his academic appointment at Vanderbilt University Medical Center. Dr. Claassen is a board-certified neurologist and internationally recognized expert in neurodegenerative diseases, with more than two decades of clinical and translational research in mov

    3/4/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $APLM
    $ATHE
    $CRIS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Curis with a new price target

    H.C. Wainwright resumed coverage of Curis with a rating of Buy and set a new price target of $17.00

    5/19/25 8:52:11 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ladenburg Thalmann initiated coverage on Numerical Tech with a new price target

    Ladenburg Thalmann initiated coverage of Numerical Tech with a rating of Buy and set a new price target of $1.45

    5/5/25 8:32:14 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Alterity Therapeutics downgraded by The Benchmark Company

    The Benchmark Company downgraded Alterity Therapeutics from Speculative Buy to Hold

    2/3/25 7:02:17 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $APLM
    $ATHE
    $CRIS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Business Officer Wambeke David J. bought $670,400 worth of shares (1,000,000 units at $0.67) (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    3/3/26 8:49:19 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Wambeke David J.

    3 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    3/3/26 8:39:31 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Chief Technology Officer Mertens Steve covered exercise/tax liability with 7,376 shares, decreasing direct ownership by 5% to 153,047 units (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    2/20/26 2:27:42 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    $AFIB
    $APLM
    $ATHE
    $CRIS
    SEC Filings

    View All

    SEC Form F-3 filed by Apollomics Inc.

    F-3 - Apollomics Inc. (0001944885) (Filer)

    3/9/26 5:16:51 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by NeuroOne Medical Technologies Corporation

    DEF 14A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)

    3/9/26 8:00:30 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Alterity Therapeutics Limited

    6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)

    3/9/26 8:00:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $APLM
    $ATHE
    $CRIS
    Leadership Updates

    Live Leadership Updates

    View All

    Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor

    MELBOURNE, Australia and SAN FRANCISCO, March 04, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that Daniel O. Claassen, M.D., M.S., was appointed Chief Medical Advisor and will begin his role in March 2026. As a tenured professor, Dr. Claassen will also retain his academic appointment at Vanderbilt University Medical Center. Dr. Claassen is a board-certified neurologist and internationally recognized expert in neurodegenerative diseases, with more than two decades of clinical and translational research in mov

    3/4/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

    − Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter.Regulatory planning activities advancing toward a pivotal Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026.Ongoing partnering and strategic discussions with pharmaceutical companies and corporate advisers to explore non-dilutive pathways to fund Phase 3 development.Board and executive leadership strengthened to support Alterity through its next stage of clinical development, partnering and comme

    1/30/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026

    MELBOURNE, Australia and SAN FRANCISCO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to shareholders.  Dear Shareholders, Our goal for 2025 was the successful completion of the Phase 2 program investigating our lead asset, ATH434, in multiple system atrophy (MSA) and to produce data that would enable us to advance into Phase 3. We accomplished this mission and then some. Results from the Phase 2 trials were resoundingly favourable with data demonstrating the drug to be safe and well-tolerated

    1/21/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $APLM
    $ATHE
    $CRIS
    Financials

    Live finance-specific insights

    View All

    Next-Generation Platforms Scale Across Energy, Wellness, and Smokeless Consumer Segments

    Issued on behalf of Doseology Sciences Inc.Equity-Insider.com VANCOUVER, BC, March 5, 2026 /CNW/ -- Consumers are voting with their wallets, and zero-sugar is winning. Zero-sugar beverages are driving 6x more dollar growth than regular varieties as buyers actively choose clean-label products with natural sweeteners and functional ingredients[1]. The global market is forecast to expand from $350 billion in 2024 toward $500 billion by 2029, fueled by health-conscious consumers who want naturally functional products without heavy processing[1]. This structural shift is creating validated demand for precision-dosed, portable formats across energy and wellness categories, positioning Doseology Sc

    3/5/26 9:00:00 AM ET
    $HLF
    $NHTC
    $NMTC
    Other Pharmaceuticals
    Health Care
    Consumer Specialties
    Consumer Discretionary

    Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025

    LEXINGTON, Mass., Oct. 30, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025, at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast on the same day at 4:30 p.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast

    10/30/25 4:00:00 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)

    Company invests in DeSci blockchain innovation and purchases native coin of ResearchHub, a decentralized science platform co-founded by Coinbase CEO, Brian Armstrong SARASOTA, FL, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced its initial purchase of ResearchCoin (RSC) as part of its expanded digital assets treasury strategy designed to capture long-term value from emerging multi-chain opportunities. RSC is the native token of ResearchHub, a decentralized platform designed to advance scientific collaboration and discovery. ResearchHub was

    10/6/25 8:10:00 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    $AFIB
    $APLM
    $ATHE
    $CRIS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Acutus Medical Inc.

    SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

    12/16/24 9:52:56 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by NeuroOne Medical Technologies Corporation

    SC 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)

    11/26/24 8:42:10 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc.

    SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

    11/14/24 8:51:58 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care